WHO probing Indian cough syrup after 66 children die in The Gambia

WHO probing Indian cough syrup after 66 children die in The Gambia

The Gambia
The Gambia. Photo: afp / AFP
Source: AFP

PAY ATTENTION: Сheck out news that is picked exactly for YOU ➡️ find “Recommended for you” block on the home page and enjoy!

The World Health Organization (WHO) issued an alert Wednesday over four cough and cold syrups made by Maiden Pharmaceuticals in India, warning they could be linked to the deaths of 66 children in The Gambia.

The UN health agency also cautioned that the contaminated medications may have been distributed outside of the West African country, with global exposure "possible."

WHO chief Tedros Adhanom Ghebreyesus told reporters that the four cold and cough syrups in question "have been potentially linked with acute kidney injuries and 66 deaths among children."

"The loss of these young lives is beyond heartbreaking for their families."

Tedros said that WHO was also "conducting further investigation with the company and regulatory authorities in India."

Read also

Uganda Ebola outbreak death toll 29, says WHO

According to the medical product alert issued by WHO Wednesday, the four products are Promethazine Oral Solution, Kofexmalin Baby Cough Syrup, Makoff Baby Cough Syrup and Magrip N Cold Syrup.

PAY ATTENTION: Follow us on Instagram - get the most important news directly in your favourite app!

"To date, the stated manufacturer has not provided guarantees to WHO on the safety and quality of these products," the alert said, adding that laboratory analysis of samples of the products "confirms that they contain unacceptable amounts of diethylene glycol and ethylene glycol as contaminants."

Those substances are toxic to humans and can be fatal, it said, adding that the toxic effect "can include abdominal pain, vomiting, diarrhoea, inability to pass urine, headache, altered mental state and acute kidney injury which may lead to death."

The Gambia's health ministry asked hospitals last month to stop using a syrup paracetamol, pending the outcome of an investigation, after at least 28 children died of kidney failure.

Read also

Spotlight on synthetic tissues and mRNA for chemistry Nobel

WHO said that information received from India's Central Drugs Standard Control Organisation indicated that the manufacturer had only supplied the contaminated medications to The Gambia.

"However, the supply of these products through informal or unregulated markets to other countries in Africa, cannot be ruled out," the UN agency said in an email.

"In addition, the manufacturer may have used the same contaminated material in other products and distributed them locally or exported," it warned.

"Global exposure is therefore possible."

Tedros urged caution, calling on all countries to work to "detect and remove these products from circulation to prevent further harm to patients."

The Gambian health ministry's advice on syrup paracetamol was issued on September 9, a month after investigators reported the death of at least 28 children aged five months to four years from acute renal failure.

The investigation had been opened on July 19. No details were given as to when the children died.

New feature: Сheck out news that is picked for YOU ➡️ find “Recommended for you” block on the home page and enjoy!

Source: AFP

AFP avatar

AFP AFP text, photo, graphic, audio or video material shall not be published, broadcast, rewritten for broadcast or publication or redistributed directly or indirectly in any medium. AFP news material may not be stored in whole or in part in a computer or otherwise except for personal and non-commercial use. AFP will not be held liable for any delays, inaccuracies, errors or omissions in any AFP news material or in transmission or delivery of all or any part thereof or for any damages whatsoever. As a newswire service, AFP does not obtain releases from subjects, individuals, groups or entities contained in its photographs, videos, graphics or quoted in its texts. Further, no clearance is obtained from the owners of any trademarks or copyrighted materials whose marks and materials are included in AFP material. Therefore you will be solely responsible for obtaining any and all necessary releases from whatever individuals and/or entities necessary for any uses of AFP material.

Online view pixel